deltatrials
Terminated PHASE2 INTERVENTIONAL 3-arm NCT04406272

VB-111 in Surgically Accessible Recurrent/Progressive GBM

A Randomized, Controlled Phase II Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the Viral Cancer Therapy Ofranergene Obadenovec (VB-111) in Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

Sponsor: Dana-Farber Cancer Institute

Conditions Glioblastoma Recurrent Glioblastoma
Interventions Bevacizumab Placebo Surgery VB11
Updated 15 times since 2020 Last updated: May 22, 2025 Started: Aug 1, 2020 Primary completion: Aug 1, 2024 Completion: Aug 1, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Trial stopped at request of VBL Therapeutics, as they are no longer pursuing their VB-111 development program.

Other terminated trials from Dana-Farber Cancer Institute

See all terminations from Dana-Farber Cancer Institute

Other Glioblastoma trials with similar outcome

Browse all Glioblastoma trials

A PHASE2 clinical study on Glioblastoma and Recurrent Glioblastoma, this trial is terminated or withdrawn. The trial is conducted by Dana-Farber Cancer Institute and has accumulated 15 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Jul 2022 · 8 months · monthly snapshot~Jul 2022 – ~Jan 2023 · 6 months · monthly snapshot~Jan 2023 – ~Aug 2023 · 7 months · monthly snapshot~Aug 2023 – ~Nov 2023 · 3 months · monthly snapshot~Nov 2023 – ~Apr 2024 · 5 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jul 2025 · 10 months · monthly snapshot~Jul 2025 – present · 14 months · monthly snapshot

Change History

15 versions recorded

  1. Jul 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Jul 2025 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Nov 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 10 earlier versions

  1. Aug 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Jul 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  4. Nov 2021 — Jul 2022 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  5. Sep 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  7. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  8. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. Jul 2020 — Sep 2020 [monthly]

    Not Yet Recruiting PHASE2

  10. Jun 2020 — Jul 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dana-Farber Cancer Institute
  • Vascular Biogenics Ltd. operating as VBL Therapeutics
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations